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Abstract 
Background: Bipolar disorder (BPD) is a common psychiatric disorder, characterized by 
recurrent episodes of mania/hypomania and depression. Similar to a majority of other 
psychiatric disorders, complete aetiology and/or pathogenesis are unknown in BPD. Modern 
research has proposed an association between an impaired blood-cerebrospinal fluid (CSF) or 
blood-brain barrier and subgroups of patients suffering from different psychiatric conditions, 
such as schizophrenia, depression and other affective disorders. The purpose of this study was 
to evaluate whether dysfunction of the blood-brain barrier is over represented in a cohort of 
bipolar patients, compared to an age- and gender-matched healthy control group, i.e. quantify 
and further validate past research findings and aim the study against a specific disorder where 
documentation is limited. 
Methods:  Subjects included 134 BPD patients and 86 healthy controls. Serum and CSF were 
collected from all subjects and analyzed for albumin concentration by immunonephelometry, 
where after CSF/serum albumin ratio was determined by dividing CSF with serum albumin 
concentration. CSF/serum albumin ratio was then compared between patients and controls 
using Mann-Whitney U-test. 
 Results: CSF/serum albumin ratio was significantly elevated in BPD patients as compared to 
controls, suggesting impairment of the blood-brain barrier in BPD. When excluding 35 
patients and controls, on magnetic resonance imaging (MRI) of the brain displaying signs of 
somatic or neurological diseases known to impinge the blood-brain barrier, the significant 
difference in CSF/serum albumin ratio between BPD patients and controls remained. 
Moreover, after stratifying patients according to type of BPD, the group consisting of BPD I 
patients significantly excelled. 
Conclusions: The findings statistically establish that a subgroup of individuals with BPD has 
elevated CSF/serum albumin ratio, indicating that an impaired blood-brain barrier may play a 
role in or reflect the disease process in BPD, although the complete mechanisms causing the 
impairment are still unknown and further studies are required. 
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 1. Introduction 
1.1. The past 
For more than 100 years mankind has tried to find the aetiology and/or pathogenesis of 
psychiatric disorders as bipolar disease (BPD), depression and schizophrenia. Already in the 
late-nineteenth century several scientists, such as Emil Kraepelin, believed that some kind of 
bacteria was involved in the aetiology [1]. One of the grounds behind this theory was that 
many of the patients suffering from microbial diseases developed psychiatric disorders. 
Accordingly, the eager to find an explanation to why some people develop psychiatric 
disorders has driven scientists and researchers for a long time, during which several infectious 
agents have been suggested as possible underlying factors;  Treponema pallidum, Borrelia 
burgdorferi, herpes simplex viruses, Epstein-Barr virus, cytomegalo virus, influenza, measles, 
rubella, mumps, polio, etc. [2]. 
The interest in finding the aetiology for psychiatric disorders has varied during the last 100 
years. For example, the research in this field, in the western world, became less intense when 
Sigmund Freud presented his theories with psychological explanations to psychiatric illness in 
the 1930´s. However, the theories that imply that infections can cause, or at least somehow are 
linked to, psychiatric illness are still wide spread among neurological researchers. 
 
1.2. The present 
Modern research indicates that, even before birth and during childhood, infectious agents can 
increase the risk of psychotic syndromes and schizophrenia later in life [3-9]. Studies during 
the last decade postulate that the inflammation process itself may be involved in the 
pathomechanisms linked to e.g. depression. Increased CRP (C-reactive protein, an acute-
phase protein that rises in response to inflammation) levels in blood from depressed patients, 
and after a depressive state, have been observed, which supports an involvement of 
 inflammation in the disease [10-14]. In 2001, Zorrilla et al. published a comprehensive meta-
analysis, consisting of more than 180 studies of patients with depressive disorder, which 
shows that several interesting immunological changes related to the inflammation process can 
be observed in patients with depression [15]. Findings from different recent studies also 
propose a correlation between inflammatory reactions and other psychiatric disorders, both 
schizophrenia and affective ditto [16-21]. 
 
1.3. The blood-brain barrier 
In parallel to the interesting research on psychiatric illnesses and their relationships to the 
immune system, the question rises whether the inflammation in the central nervous system 
(CNS) originates from within the CNS or if it is somehow transferred through e.g. an 
impaired blood-brain barrier. If the latter assumption is correct, some individuals may be 
predisposed to psychiatric disorders if their blood-brain barriers, for some reason(s), are 
dysfunctional or more vulnerable. As there are a number of established causes of dysfunction 
in the blood-brain barrier, such as; hypoxia, head trauma, hypertension and tumours [22], it 
opens for a variety of possible aetiological factors for psychiatric disorders. Also different 
kinds of dementia illnesses have been reported to depend, to some extent, on a damaged 
barrier [23-25]. The concept that an impaired blood-brain barrier may precipitate development 
of psychiatric disorders also creates a possible interpretation of the previously mentioned 
findings [3-9], which suggest a correlation between prenatal/childhood infections and 
psychiatric illness later in life: 
An infection early in life may create a damage or vulnerability in the blood-brain barrier, 
which later in life can be an aetiological factor for psychiatric disorders. 
In analogy with the blood-brain barrier impairment theory, studies have shown a significant 
association between an impaired blood-brain barrier and patients with both paranoid 
 psychosis [26] and schizophrenia [27, 28]. Within these three rather small studies, with a total 
of 64 patients included, it was found that as many as one third of the affected patients had an 
impaired blood-brain barrier. 
Current research shows that schizophrenia shares phenotypic traits with BPD, including for 
example psychotic symptoms [29, 30]. Also epidemiological [31] and genetic studies [32, 33] 
suggest that these syndromes partially share genetic vulnerability traits, which caused us to 
hypothesize that bipolar patients may have similar defects in the blood-brain barrier. 
Moreover, a study from 1995 with 90 suicide attempters, whereof 44 were diagnosed with 
either depression or dysthymia, revealed that 18% displayed signs of an impaired blood-brain 
barrier, which significantly separated them from the controls [34]. Also, consistent with the 
blood-brain barrier dysfunction theory, a recent (2009) study in Germany on 63 treatment-
resistant affective and schizophrenic spectrum disorder patients revealed that 29% had blood-
brain barrier dysfunctions. This study even showed that as many as 38% (9/24) of the 
affective spectrum disorder (including bipolar disorder) patients exhibited blood-brain barrier 
dysfunction [35]. 
 
1.4 Means to measure the blood-brain barrier dysfunction 
The best-established biomarker for the integrity of the blood-brain barrier is the ratio of the 
albumin concentration in CSF to serum or plasma (CSF/serum albumin ratio) [36]. Albumin is 
synthesized in the liver and released to plasma, where it serves as a carrier protein and colloid 
oncotic pressure regulator. It enters the CSF across the blood-CSF barrier in plexus 
choroideus and the blood-brain interstitial fluid barrier along the capillaries. Comparing 
albumin levels in lumbar CSF and serum gives an estimate of the integrity of the blood-brain 
barrier as a whole, at least for this particular type of molecule. Around 150 times lower 
 concentration of albumin is expected in the CSF compared with serum, providing the blood-
brain barrier function is intact [36]. 
 
1.5. Bipolar disorder 
Bipolar disorder (BPD) is a common psychiatric disorder, affecting about 1-3 % of the 
population [37]. It is characterized by recurrent episodes of mania (or hypomania) and 
depression, interspaced with periods of euthymic mood [38]. Cognitive dysfunction is 
frequent, also in euthymic bipolar patients, including impairment in executive function and 
verbal memory  [39]. The disease often, indirectly, affects families, friends and employers, 
and can be the actual background to homelessness, financial troubles, broken relationships, 
drug abuse, suicide and other tragic life stories. According to DSM IV, BPD is classified in 
three different subtypes; BPD I (presuming at least one episode of mania), BPD II (recurrent 
depressions and circles of hypomania) and BPD NOS ([not otherwise specified] patients with 
bipolar affective disease not fulfilling criteria for I or II). In this study we have further divided 
patients into BPD III (merely mania/hypomania induced by antidepressives) and BPD V 
(unipolar depressions and heredity for BPD), according to e.g. Akiskal et al. [40]. In addition, 
we have included three patients diagnosed, according to DSM-IV, with cyclothymia (circles 
of hypomania during two years and not fulfilling criteria for actual depression) or SDM 
([schizoaffective disorder manic type] either depressive or manic episode, concurrent with 
schizophrenia). 
 
1.6. Aim 
The purpose of this study was to evaluate whether dysfunction of the blood-brain barrier is 
over represented in a cohort of bipolar patients, compared to a healthy control group, which 
thereby quantify and further validate past research findings that proposes a correlation 
 between a damaged blood-brain barrier and psychiatric illness. Additionally, subjects in this 
study consist of a diagnostically heterogeneous large patient group, which is not well 
documented with regards to blood-brain barrier function in previous studies. Also, the study 
aimed to control if a potential difference in blood-brain barrier function, between patients and 
controls, is still of significance when the subjects are followed up and further investigated to 
find supplementary medical conditions, or other confounding factors, which may be the actual 
cause of the blood-brain barrier dysfunction. 
 
Subjects and methods 
2.1. Patients 
Patients were recruited from the St. Göran bipolar project, enrolling patients from the bipolar 
unit at the Northern Stockholm Psychiatric Clinic, Stockholm, Sweden. The BPD group 
consisted of 134 patients and their respective diagnoses where distributed as follows: Bipolar 
disorder type I; 64 patients (41 women, 23 men), Bipolar disorder type II; 53 patients (32 
women, 21 men), bipolar disorder type III; 7 patients (2 women, 5 men), bipolar disorder type 
V; 1 patient (man), bipolar disorder NOS; 6 patients (3 women, 3 men), cyclothymia; 1 
patient (woman), schizoaffective disorder manic type; 2 patients (1 woman, 1 man). 
Supplementary demographics and clinical characteristics of the study population are 
presented in table 1. 
The key clinical assessment instrument used for diagnostics was the Affective Disorder 
Evaluation (ADE), developed for the NIMH-sponsored Systematic treatment Enhancement 
Program of Bipolar Disorder (STEP-BD) [41]. The ADE interviews were conducted by board-
certified psychiatrists working at the tertiary care bipolar out-patient unit or by residents in 
psychiatry completing their psychiatric training at this unit [42]. Furthermore, instruments 
utilized to exclude not suitable patients with other psychiatric diagnoses, alcohol or drug 
 abuse were three psychiatric tools; Mini International Neuropsychiatry Interview (M.I.N.I) 
[43],  the Alcohol Use Disorders Identification Test (AUDIT) [44] and the Drug Use 
Disorders Identification Test (DUDIT) [45], whereof the two latter are self-report 
questionnaires. Other exclusion criteria were inability to complete the standard clinical 
assessment or incapability of providing informed consent. The patient data was presented at a 
diagnostic case conference, where the final diagnostic decision was made by a consensus 
panel of experienced board-certified psychiatrists specialized in bipolar disorder. The general 
criteria for inclusion were patients at the age of minimum 18 years, who met the DSM-IV 
criteria for any bipolar disorder, i.e., type I, II, NOS (not otherwise specified), cyclothymia, or 
schizoaffective syndrome manic type. 
Information was collected about number of depressive, manic, and mixed episodes, as well as 
age at onset, history of psychosis and current medications. The lifetime severity of bipolar 
disorder was rated using the Clinical Global Impression (CGI) rating scales. This 7-point 
scale reflects the clinician’s rate of the severity: 1=normal or not at all ill, 2=borderline 
mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill and 7=extremely ill. 
For ethical reasons, patients continued to take their prescribed medications at the time of CSF 
sampling. More detailed information about the work-up and diagnostic assessments have been 
described previously [42]. 
 
2.2. Controls 
The subjects collected to get age- and sex-matched healthy, population-based, controls 
consisted of 86 individuals picked in a random selection, by Statistics Sweden (SCB), and 
contacted by mail. Persons interested of participating in the study contacted the study team, 
which conducted a preliminary telephone screening to exclude severe mental health and 
neurological issues as well as substance abuse. Eligible individuals were scheduled for a one-
 day comprehensive assessment. Of the controls that received the invitation mail, 14% 
contacted the research team. This is on par with other studies of similar nature according to 
SCB. Of those controls that volunteered, 75 were excluded at the telephone interview mainly 
due to drug use (N=16), changed their mind (N=14), somatic ill-health (N=12), metal objects 
in body excluding MRI (N=10), heredity in first degree relative of bipolar disorder or 
schizophrenia (N=9), ongoing mental health diagnoses (N=6), pregnancy (N=5), and moved 
out of area (N=2). One subject had no documented reason for exclusion. Furthermore, one 
subject failed to show up for the assessments. 
Control subjects underwent a psychiatric interview by experienced clinicians using MINI 
[43], which included the affective disorders section, and the same investigations the patients 
have undertaken, including self-rating scales, somatic tests, blood tests and lumbar puncture. 
Because the assessments of controls might reveal pathology, case conferences were held 
between examining clinicians, primary investigator and study coordinator in order to decide 
whether or not including such individuals in the study. It was thus decided to allow past minor 
depressive disorders, isolated episodes of panic disorder, eating disorders or obsessive 
compulsive disorder which remitted spontaneously or with short term psychotherapy. 
Substance abuse was screened for at telephone interview by the nurse, in the psychiatric 
interview, by AUDIT [44] and DUDIT [45] as well as by determining serum carbohydrate-
deficient transferrin (CDT). Over consumption of alcohol as revealed by CDT or responses in 
self-tests indicating large consumption (> 8 standard drinks per time more than 2 times per 
week, and/or amnesia and/or loss of control more than once per month) resulted in exclusion 
of these subjects from the study. 
Other exclusion criteria were neurological conditions other than mild migraines, untreated 
endocrinological disorders, pregnancy, dementia, recurrent depressive disorder, suspected 
 severe personality disorders (based on interview and SCID-II personality assessment), a 
family history of schizophrenia or bipolar disorder in first-degree relatives. 
 
2.3. Ethics 
The study was approved by the Regional Ethics Committee in Stockholm and conducted in 
accordance with the latest Helsinki Protocol. All enrolled patients and controls consented 
orally and in writing to participate in the study after the nature of the procedure had been fully 
explained. 
 
2.4. MR-imaging  
During the study 114 of 134 patients and 85 of 86 controls underwent magnetic resonance 
imaging (MRI) of the brain. MRI scans were acquired at the MR Research Centre, Karolinska 
University Hospital, Stockholm. Sagittal and coronal T1 weighted, axial and coronal T2 
weighted, and axial fluid attenuation inversion recovery (FLAIR) T2 weighted scans were 
acquired using a 1.5T scanner (General Electric Signa Excite) and subsequently examined for 
clinically significant anatomical abnormalities by a senior radiologist.  
 
2.5. CSF sampling 
CSF sampling (lumbar puncture) was performed when the participants were in a stable 
euthymic mood. Subjects fasted overnight before the CSF collection, which occurred under 
standard conditions at 9.00 a.m. The spinal needle was inserted into the L3/L4 or L4/L5 
interspace, withdrawing a total volume of 12 ml of the CSF (gently inverted to avoid gradient 
effects) which were divided into 1.0-1.6 ml aliquots and subsequently stored at -80˚C pending 
analysis. Identical procedures were performed for both patients and controls.  
 
 2.6. Analyses of the blood-brain barrier function 
To detect impairment of the blood-CSF barrier function in the subjects, the ratio between the 
albumin concentration in the cerebrospinal fluid (mg/L) and that in the serum (g/L) were 
determined. An increased CSF/serum ratio was interpreted as an impairment of the blood-
brain barrier [46-49]. Albumin levels were measured in clinical routine by 
immunonephelometry on a Beckman Immage Immunochemistry system (Beckman 
Instruments, Beckman Coulter, Brea, CA, USA). Intra- and inter-assay coefficients of 
variation were below 10% for all analyses. 
All biochemical analyses and measurements were performed at the Clinical Neurochemistry 
Laboratory in Mölndal, Sweden, by experienced and board-certified laboratory technicians, 
blind with respect to clinical information, using methods accredited by the Swedish Board for 
Accreditation and Conformity Assessment (SWEDAC).  
 
2.7. Statistics 
The statistics software packages Prism 5 (Graph Pad, La Jolla, USA) and PASW Statistics 18 
(IBM, New York, USA) were used for the statistical analysis. As the quantitative data were 
not normally distributed, non-parametric methods were used. When comparing data between 
two or more groups, we used the Mann-Whitney U-test, or the Kruskal-Wallis test with 
Dunn’s post hoc test, respectively. For dichotomous variables Fisher’s exact test was utilized 
and correlation analysis was performed using Spearman’s rho coefficient. All p-values lower 
than 0.05 were regarded as significant.  
 
  
 3. Results 
3.1. Demographics 
We compared data from 134 CSF and serum samples collected from patients suffering from 
BPD with data from 86 healthy, age- and sex-matched individuals (Table 1). As expected, the 
patient group did not differ from the control group in respect to sex (p=0.58) or age (p=0.53). 
There was a significant difference in CSF/serum albumin ratio between men and women in 
the patient group (p<0.0001, Figure 1a) and we could, also in the control group, see a 
difference between men and women, although not significant (p=0.12, Figure 1b). A 
significant correlation between CSF/serum albumin ratio and age was notable in both patient 
and control groups (rs= 0.31, p=0.0003, and rs=0.33, p=0.0022, respectively, Figure 2a and 
2b). 
 
 3.2. Patient-controls comparisons 
CSF/serum albumin ratio was significantly elevated in BPD group as compared to control 
group (p=0.0093, Figure 3a). When stratifying the patient group according to BPD subtype (I, 
II and NOS, NOS including type III/V/NOS/Cycl/SDM) patients with increased CSF/serum 
albumin ratio were found in all diagnostic subgroups, although most patients with elevated 
albumin ratio were found in the BPD I subgroup (p=0.046, Figure 4a). From the scatter plots 
it was evident that a limited number of BPD patients had clearly elevated albumin ratios, and 
that these patients contributed the most to the significant difference in albumin ratio on a 
group level. 
When excluding a total of 35 patients and controls displaying abnormal MRI findings (as 
Wilson´s disease, multiple sclerosis and meningioma) the p-value slightly changed, although a 
statistically significant difference between cases and controls remained (p=0.020, Figure 3b). 
Again, after excluding patients and controls with positive MRI findings, stratifying patients 
 according to BPD subtype (I, II and NOS), the statistical differences remained fairly intact 
and the subgroup of BPD I patients still excelled (p=0.062, Figure 4b). 
CSF/serum albumin ratio did not correlate with any of the following parameters; experienced 
psychosis or not, CGI, or number of manic or depressive episodes (data not shown), although 
correlation were found with both age at onset and duration of illness (rs= 0.16, p=0.059, and 
rs= 0.20, p= 0.024, respectively, Figure 5a and b). There were no significant differences in 
CSF/serum albumin ratio between patients receiving no treatment, standard lithium treatment, 
antiepileptic drugs, or antidepressives (data not shown). However, there was a strongly 
significant difference between CSF/serum albumin ratio and treatment with antipsychotic 
drugs (p=0.0003, Figure 6). 
In addition, we also compared the CSF/serum albumin ratio from both patient and control 
groups to the age-adjusted reference limits normally used in our laboratory (Table 2), noting 
that 20 (15%) of the BPD patients had albumin ratios above reference limits as well as 7 (8%) 
of the controls. When comparing the patients to controls, with respect to elevated CSF/serum 
albumin ratio according to mentioned reference values, no statistical significance was obvious 
(p=0.15) 
 
Discussion  
4.1. Findings and interpretations 
When comparing CSF/serum albumin ratio in a population of patients suffering from BPD of 
different types with an age- and sex-matched control group consisting of healthy individuals, 
we found that the CSF/serum albumin ratio was significantly elevated in BPD patients. This 
finding indicates that an impairment of the blood-brain barrier is more common among BPD 
patients than in a healthy population. Based on similar past findings in studies made on 
patients with different psychiatric conditions such as paranoid psychosis, schizophrenia and 
 affective disorders [26-28, 34, 35], combined with the suggested genetic relation between 
most mentioned disorders and BPD [29-33],  we expected to find a subgroup, also among the 
patients in our study group, with an increased CSF/serum albumin ratio. 
Significant differences were found in CSF/serum albumin ratio when comparing men to 
women in the BPD group, but not in the control group. The differences in CSF/albumin ratio 
between men and women are interesting, raising e.g. the question whether separate reference 
values should be used in clinic, although it is not relevant in this patient-control sex-matched 
study. Also the observation that a significant correlation between CSF/serum albumin ratio 
and age was notable in both patient and control group is considered irrelevant in this study, 
since patients and controls are age-matched as well. 
We have ruled out possible positive correlations between patients with blood-brain barrier 
impairment and; history of psychosis or not, CGI, and number of manic or depressive 
episodes, in order to ensure that these variables are no confounders. Regarding age at onset 
and duration of illness we found a correlation between CSF/serum albumin ratio and both 
these items, but the slope of the correlation was not very far from zero and thus considered 
clinically irrelevant. After excluding 20 patients and 15 controls, displaying signs of organic 
injuries from e.g. Wilson’s disease or overt multiple sclerosis in the brain MRIs, we repeated 
Mann-Whitney tests, which revealed that even now our BPD patients were over represented 
in the category with impairment of the blood-CSF barrier.  
 
As we, by screening tests, interviews, MRI and clinical diagnostics, have eliminated many 
known differential diagnoses [23-25] and other factors [22] that may cause the increased 
CSF/serum albumin ratio or the impairment of the blood-CSF barrier, it is possible to make 
the interpretation that impairment and/or elevated ratio may be caused by one of, or a 
combination of, the following factors: 
  BPD in itself. 
 Side effects from either BPD or medications for the bipolar disorder/other medical 
conditions.  
 An unknown element (see; 4.3. Analyses, albumin ratio and blood-CSF barrier, 
advantages and limitations, for examples) before, or during, the onset of the BPD, 
indicating that the impairment/elevated ratio may have caused or acted as a triggering 
factor for BPD. 
 
Obviously, we can not leave out the possibility that, despite thorough psychiatric and 
neurological evaluation, the diagnostic tools for ruling out other medical conditions or factors, 
affecting the blood-brain barrier, used in this study may be too limited. 
Noteworthy is also the fact that, after stratifying patient groups according to type of bipolar 
disorder, we can observe that most patients with elevated albumin ratio were found in the 
BPD I subgroup, both before and after exclusion of patients and controls displaying abnormal 
MRI findings, which, with a cautious interpretation, may suggest a stronger correlation 
between the manic state of the bipolar disorder and an impaired blood-brain barrier. 
Incidentally, we discovered that as many as 20 (15%) of the BPD patients had a CSF/serum 
albumin ratio above the age-adjusted upper reference limit used in our laboratory as compared 
to 7 (8%) of the controls, nevertheless no statistical significance between the groups, with 
respect to elevated CSF/serum albumin ratio, was to be found. We have decided not to make 
any interpretation of this finding, see both; 4.2. Patients and controls, advantages and 
limitations, as well as; 4.3. Analyses, albumin ratio and blood-CSF barrier, advantages and 
limitations, for comments regarding the decreased power in comparisons between patient data 
and historical reference values. 
   
 4.2. Patients and controls, advantages and limitations 
All patients included in this study were recruited, in euthymic state, from a bipolar unit at a 
psychiatric clinic in Stockholm, Sweden. They were all diagnosed with some type of BPD by 
skilled psychiatrists and evaluated using a number of psychiatric tools, including ADE [41] 
for clinical assessment and MINI [43] for excluding patients with other psychiatric disorders 
(see methods). To further ensure the liability of the diagnostic evaluation the patient data was 
discussed at a diagnostic case conference, where the final diagnostic decision was made by a 
consensus panel of experienced board-certified psychiatrists specialized in bipolar disorder. 
 
Since a number of patients during the time of the CSF and serum sampling were using 
different kinds of prescribed drugs (as well as combinations of drugs) for the bipolar disorder, 
and in some cases other medical conditions, we can not completely rule out the potential long-
term effect they may have on the blood-brain barrier. However, our study showed no 
significant difference in CSF/serum albumin ratio between patients treated with lithium, 
antiepileptic or antidepressive drugs, and the authors are not aware of any research describing 
such effect/s. 
On the other hand, we found that patients treated with antipsychotic drugs had higher 
CSF/serum albumin ratio as a group. This may suggest an association between blood-brain 
barrier dysfunction and severity of disease (in clinical practice, mostly patients with 
treatment-resistant BPD are considered for antipsychotic regimes) or that the drugs itself 
somehow affects the blood-brain barrier. In advantage of the latter hypothesis, haloperidol 
(antipsychotic drug) has been found to alter the BBB permeability in a rat model [50]. 
Additionally, no association was found between CSF/serum albumin ratio and any of the 
following items: experienced psychosis or not, number of manic episodes, number of 
depressive episodes, which all may be considered as factors reflecting the severity of disease. 
 More research is needed to examine the precise cause-and-effect relationships underlying the 
association between blood-brain barrier dysfunction and the use of antipsychotic drugs. For 
more possible effects from drugs on the blood-CSF barrier, see: 4.3. Analyses, albumin ratio 
and blood-CSF barrier, advantages and limitations.  
Several past studies of the blood-brain barrier in patients with psychiatric disorders have, as a 
comparison to the patient data, used historical reference values constructed either from more 
or less heterogeneous disease groups [47]or neurologically and psychiatrically healthy 
individuals[48]. In our opinion this decreases the power to detect small differences in 
CSF/serum albumin ratio, as compared to our approach of using data derived in parallel from 
age- and gender-matched healthy controls. All controls were evaluated in a telephone based 
interview to exclude mental illness and symptoms of neurological disease, followed by a one-
day comprehensive psychiatric assessment including the same investigations and psychiatric 
test tools as the patients, in order to ensure mental and neurological health. Also case 
conferences were conducted with examining clinicians, primary investigators and study 
coordinator to decide whether or not to include specific controls in the study. Some 
individuals were allowed in the control group despite minor depressive disorders, isolated 
episodes of panic disorder, eating disorders or obsessive compulsive disorder which remitted 
spontaneously or with short term psychotherapy, which may have influenced the study, 
although the experienced case conference decided the risk was exiguous. For more advantages 
of this study compared to studies that used previously mentioned reference values [47], see: 
4.3. Analyses, albumin ratio and blood-CSF barrier, advantages and limitations.  
Kornhuber et al. have proposed a correlation between an impaired blood-brain barrier and 
alcohol consumption [51]. To rule out possible effects from alcohol on the CSF/serum 
albumin ratio in this study both patients and controls have been screened for alcohol- and 
other substance abuse by AUDIT [44] and DUDIT [45], as well as by determining serum 
 carbohydrate-deficient transferrin (CDT). Also, there are no documented studies on effects on 
the blood-brain barrier after completed detoxification or on subjects with a past history of 
alcohol abuse, yet these variables should be considered. 
 
4.3. Analyses, albumin ratio and blood-CSF barrier, advantages and limitations 
All CSF sampling, as well as CSF and serum analyses, were conducted under standard 
conditions and standard procedures, and also conducted identical in terms of patients and 
controls. The ratio between the albumin concentration in the cerebrospinal fluid (mg/L) and 
that in the blood serum (g/L) were determined to evaluate the function of the blood-brain 
barrier, which by several authors is considered as the gold standard [35, 52, 53]. Increased 
CSF/serum albumin ratio in patients, compared to controls, was interpreted as an impairment 
of the blood-brain barrier in BPD [36]. This interpretation is accepted and used as standard 
procedure among neurologists and scientists in the neurological field [46-49]. 
A possible bias when comparing past established reference values of albumin ratios (derived 
with X ml CSF withdrawn) to new patient data (derived with Y ml CSF withdrawn) is that 
albumin ratio decreases when volume of CSF withdrawn from the subject increases 
(explained by the rostro-caudal concentration gradient [35]), which in this study has been 
eliminated by withdrawing the same volume of CSF from both patients and controls. 
Also, by age-matching the patients and controls, along with application of CSF/serum ratios, 
this study ruled out possible biases caused by, probably all known, age-related differences in 
CSF (as well as serum) albumin levels. Another advantage with age-matched, as well as sex-
matched, patient-control studies, instead of comparing CSF/serum albumin ratios to 
mentioned reference values [47], is the obvious differences in ratio correlating to sex and age 
in our study. 
Reduced CSF flow rate induces, according to general assumptions and experience in clinical 
neurology, increased concentrations of albumin in the CSF, which may alter the CSF/serum 
 ratio. According to Bechter et al. (2010), a  variety of different mechanisms, such as;  “low 
CSF production rate, increased flow resistance in the subarachnoid space, or reduced outflow 
into venous blood due to blocked arachnoid villi” [35] are proposed to reduce CSF flow rate. 
This indicates that in absence of past MRI and CSF flow rate charts from all patients and 
controls it is not possible to completely rule out the possibility that any of these mechanisms 
impinge the result of this study, although recent MRI and clinical assessment should have 
eliminated most mechanisms. However, research regarding the influence of medical treatment 
on CSF flow rate is limited and as all subjects in this study continued to take their prescribed 
medications at the time of CSF sampling, this source of bias should be considered. 
It is notable that there are a number of already established causes of dysfunction in the blood-
brain barrier, such as; hypoxia, head trauma, hypertension and tumours [22]. Furthermore, 
different kinds of dementia illnesses, vascular dementia in particular, are characterized by 
barrier dysfunction [23-25]. All these causes are however also, most likely, ruled out (by MRI 
and thorough clinical evaluation) in the current study. 
Another observandum is that this study merely provides the albumin concentrations and 
CSF/serum ratios during a euthymic period (trait marker). Changes in albumin concentrations, 
as well as changes in CSF flow and blood-brain barrier function that may affect the albumin 
concentrations, might be more apparent during manic and/or depressive episodes (state 
marker). Nevertheless, it may also be argued that measuring albumin concentrations during 
euthymia provides a more reliable picture of BPD albumin concentrations, as these might be 
affected by secondary effects that appears during mania/depression (like altered sleeping 
behavior, motor activity etc.) not specific to bipolar disorder. 
  
 4.4. Conclusions 
In a well defined, diagnostically heterogeneous, cohort of patients suffering from bipolar 
disorder we discovered a subgroup of patients, displaying signs of impairment in the blood-
brain barrier. When comparing CSF/serum albumin ratios from a healthy, population-based, 
age- and sex-matched control group to data from the patient cohort significant differences 
occurred, providing compelling evidence of an association between bipolar disorder and 
impairment of the blood-brain barrier. This evidence is also in consistency with similar 
research on several different psychiatric disorders. After stratifying patients according to 
different types of bipolar disorders we can also state that the strongest association to 
CSF/serum albumin ratio was found with the BPD I subgroup, significantly separating this 
group when comparing to the other types of BPD and controls. This finding makes it tempting 
to speculate whether that the blood-brain barrier dysfunction somehow is more related to the 
manic state of the bipolar disorder. 
Unfortunately, the cross-sectional design of the study makes it impossible to address cause-
and-effect relationships underlying the detected associations as well as to designate which of 
the bipolar disorder and the blood-bran barrier impairment that came first (in somewhat 
similar to the unanswered philosophical causality dilemma about the chicken or the egg [54]), 
which both requires research with a different approach. 
On the other hand, evidence from this study should stimulate further research on longitudinal 
cohorts. Such studies could, for example, answer the question if patients with blood-brain 
barrier impairment are at increased risk of bipolar disorder or vice versa. Finally, among 
bipolar patients with blood-brain barrier damage we found a number of treatable somatic or 
neurological conditions (such as Wilson’s disease and multiple sclerosis), which underscores 
the importance of thorough somatic and neurological inquiry of patients clinically assessed 
with bipolar disorder. 
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 Figure legends 
 
Figure 1. 
Grouped scatter plot showing the sex distributions of albumin cerebrospinal/serum ratio in (a) 
bipolar patients, and (b) healthy controls. AlbQ equals cerebrospinal/serum albumin ratio. The 
red horizontal bars represent the medians.  
 
Figure 2. 
Scatter plot of age distributions and albumin cerebrospinal/serum ratio in (a) bipolar patients, 
and (b) healthy controls. AlbQ equals cerebrospinal/serum albumin ratio.  
 
Figure 3. 
Grouped scatter plot showing the subject group distributions of albumin cerebrospinal/serum 
ratio  (a) before excluding subjects with abnormal MRI, and (b) after excluding subjects with 
abnormal MRI. AlbQ equals cerebrospinal/serum albumin ratio. The red horizontal bars 
represent the medians.  
  
Figure 4. 
Grouped scatter plot showing the subject group distributions of albumin cerebrospinal/serum 
ratio  (a) before excluding subjects with abnormal MRI, and (b) after excluding subjects with 
abnormal MRI. AlbQ equals cerebrospinal/serum albumin ratio. The red horizontal bars 
represent the medians.   
 
Figure 5. 
Scatter plot of albumin cerebrospinal/serum ratio and (a) age at onset, and (b) duration of 
illness in bipolar patients. AlbQ equals cerebrospinal/serum albumin ratio.  
 
Figure 6. 
Grouped scatter plot showing the distributions of albumin cerebrospinal/serum ratio in 
patients with (yes) and without (no) prescribed antipsychotic drugs. AlbQ equals 
cerebrospinal/serum albumin ratio. The red horizontal bars represent the medians.  
  
   
Table 1.     
  Controls  (N=86) Bipolar disorder  (N=134) 
Sex (male/female) 38/48 54/80 
Age (years) 34 (28-46) 36 (28-50)
c
  
Diagnosis (BPD-I/II/III 
/V/NOS/Cycl/SDM/)
a
 
  
64/53/7/1/6/1/2/ 
Age at onset   19 (15-25)
c
 
Duration of illness   15 (9-26)
c
 
Total number of episodes   11 (7-23)
c
 
   Mania   1 (0-2)
c
 
   Depression   10 (6-20)
c
 
Psychosis (yes/no)    65/69 
CGI   4 (4-5)
c
 
Medications     
    Lithium (yes/no)   79/55 
    Anticonvulsants (yes/no)   46/88 
   Antidepressives (yes/no)   63/71 
   Antipsychotics (yes/no)   35/99 
a
 BPD I = bipolar disorder type I, BPD II = bipolar disorder type II, BPD III = bipolar 
disorder type III (hypomania induced by antidepressants), BPD V = bipolar disorder type V 
(patient with major depression and relatives with mania), NOS = Bipolar disorder not 
otherwise specified, Cycl = cyclothymia, SDM = schizoaffective disorder manic type 
b
 CGI = clinical global impression   
c
 Presented as median (interquartile range)   
     
Demographics and clinical characteristics of the study population. Presented as median 
(interquartile range) or ratio. 
 
 
 
 
Table 2.  
Children, 1,5 - 14 y/o <5,0 
Adults, 15 – 44 y/o  <6,8 
Adults, 45 – 89 y/o <10,2 
 
Upper reference limits for CSF/serum albumin ratio, used by Clinical Neurochemistry 
Laboratory in Mölndal, Sweden  
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 Populärvetenskaplig sammanfattning 
 
Har patienter med bipolär sjukdom skadad blod-hjärnbarriär? 
I ett samarbete mellan Sahlgrenska akademin och Karolinska Institutet har en studie gjorts 
med syftet att utreda om patienter som drabbats av bipolär sjukdom (tidigare kallad 
manodepressiv sjukdom), i större utsträckning än friska människor, har skador som ökar 
risken att blodburna ämnen kan ta sig till hjärnan. Studien visar att det finns ett statistiskt 
säkerställt samband mellan bipolär sjukdom och skador på, den så kallade, blod-
hjärnbarriären. 
Bakgrunden till studien är att ett flertal forskningsstudier i världen kunnat påvisa ett samband 
mellan flera psykiska sjukdomar och skador på blod-hjärnbarriären, vilken skall skydda 
hjärnan genom att fungera som ett filter mellan blod och hjärna. Exempel på tillstånd där 
dessa skador kunnat påvisas hos en större andel patienter, jämfört med andelen hos friska 
individer, är schizofreni, paranoid psykos och vissa affektiva sjukdomar, såsom depression. 
Dock har forskning om relationen mellan barriärskada och bipolär sjukdom varit begränsad 
och de studier som gjorts har innehållit få patienter, vilket gör att resultatens tillförlitlighet 
minskar. 
Genomförandet utgick från att först, med hjälp av bl.a. specialister i psykiatri, psykiatriska 
tester och undersökningar med magnetkamera, tillse att studiens 134 patienter (rekryterade 
från en bipolär-enhet på en psykiatrisk klinik i Stockholm) fått korrekt diagnos och utesluta 
andra tillstånd som kan påverka resultatet av studien. Samtidigt utsågs 86 frivilliga, friska, 
ålders- och könsmatchade personer (genom ett slumpmässigt urval av statistiska 
centralbyrån), som alla genomgick tester och undersökningar, identiska med patienternas, för 
att utesluta sjukdomar och andra tillstånd som skulle göra dem olämpliga som jämförelse- 
(kontroll-)grupp. Därefter vidtog inhämtning av provmaterial från både patienter och 
 kontrollgrupp. Materialet bestod av dels  blod (serum), och dels cerebrospinalvätska (även 
kallad ryggmärgsvätska) insamlad genom att en provtagningsnål införs mellan ländkota 3/4 
eller 4/5 (så kallad lumbalpunktion) och en liten mängd vätska dras ut. Denna 
cerebrospinalvätska (CSV), som omger nerverna fram till deras utträde ur ryggraden, 
cirkulerar hela vägen upp till skallen och är samma vätska som omger hjärnan. På laboratoriet 
analyserades sedan serum och CSV, varvid koncentrationen av albumin (ett protein som 
levern producerar och frisläpper i blodet) i dessa båda noterades. Eftersom blod-
hjärnbarriären agerar som ett filter mellan blod och CSV  skall albuminkoncentrationen, hos 
en människa med fungerande barriär, vara ungefär 150 gånger högre i blodet jämfört med i 
CSV. För att avgöra om patienterna hade en fungerande blod-hjärnbarriär dividerades 
koncentrationen av albumin i CSV med koncentrationen i serum (CSV/serum), varpå dessa 
kvoter (resultaten av divisionerna) kunde jämföras med kvoterna från den friska 
kontrollgruppen. Slutligen beräknades om det förelåg någon statistiskt etablerad skillnad 
mellan CSV/serum-kvoterna hos patientgruppen jämfört med kontrollgruppen, samt hur 
statistiskt säker denna skillnad var. 
Resultatet av studien är att man kan konstatera att en betydande andel av studiens patienter 
med bipolär sjukdom definitivt har ökad CSV/serum-kvot av albumin, vilket indikerar att 
funktionen i deras blod-hjärnbarriär är nedsatt. De bakomliggande orsakerna till bipolär 
sjukdom (liksom många andra psykiska sjukdomar) är idag okända och upptäckter i denna typ 
av studier är mycket viktiga. Genom identifiering av gemensamma defekter hos patienter med 
samma sjukdom ger man uppslag till var de bakomliggande orsakerna till sjukdomen kan 
hittas och kan därigenom styra framtida forskning på rätt väg.  
 
